Vol.59 No.4 July 2011
Arbekacin serum pharmacokinetics in patients with cardiac disease
1)Department of Pharmacy, Bell Land General Hospital, 500-3 Higashiyama, Naka-ku, Sakai, Osaka, Japan
2)Department of Surgery/Mammary Gland Surgery, Bell Land General Hospital
3)Department of Pulmonary Medicine, Bell Land General Hospital
4)Department of Pediatrics, Bell Land General Hospital
Abstract
This study retrospectively evaluated the influence of cardiac disease on the pharmacokinetics of arbekacin in 30 patients with cardiac disease as compared with that in 41 patients without cardiac disease. The pharmacokinetic parameters of arbekacin were estimated by the least-squares method. In the pharmacokinetic parameters of arbekacin, significant differences in elimination rate constant (0.158± 0.0575 vs. 0.199± 0.0777 hr-1 [mean± standard deviation] ,P< 0.05) and total serum clearance (0.0598± 0.0344 vs. 0.0769± 0.0342 L/hr/kg, P< 0.05) were found between patients without cardiac disease and those with cardiac disease. On the laboratory data, no differences in Ccr were seen in patients without cardiac disease as compared with that in those with cardiac disease (80.5± 16.0 vs. 74.7± 14.6 mL/min, P=0.304).
Our data suggested that a decreased total serum clearance exits for arbekacin in patients with cardiac disease.
Key word
arbekacin, cardiac disease, pharmacokinetics
Received
March 10, 2011
Accepted
June 7, 2011
Jpn. J. Chemother. 59 (4): 374-378, 2011
